Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 16, 2004Blood

Sustained Durability of Responses Plus High Rates of Cytogenetic Responses Result in Long-Term Benefit for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Treated with Imatinib (IM) Therapy: Update from the IRIS Study.

View Full Paper
Ask AI
Bookmark
Share

Authors

FGFrançois GuilhotInserm

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

François Guilhot (2004) studied this question.

synapsesocial.com/papers/6a16c84cc23c548e2a7b8bbbhttps://doi.org/10.1182/blood.v104.11.21.21
View Full Paper
Ask AI
Bookmark
Share